OraSure Technologies Stock Forecast, Price & News

+1.91 (+16.65 %)
(As of 09/17/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5.27 million shs
Average Volume964,386 shs
Market Capitalization$963.48 million
P/E Ratio191.14
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

OraSure Technologies logo

About OraSure Technologies

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.97 out of 5 stars

Medical Sector

601st out of 1,350 stocks

Surgical & Medical Instruments Industry

60th out of 123 stocks

Analyst Opinion: 1.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

Is OraSure Technologies a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OraSure Technologies stock.
View analyst ratings for OraSure Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than OraSure Technologies?

Wall Street analysts have given OraSure Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OraSure Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OraSure Technologies?

OraSure Technologies saw a decline in short interest in August. As of August 13th, there was short interest totaling 4,120,000 shares, a decline of 25.1% from the July 29th total of 5,500,000 shares. Based on an average daily volume of 890,000 shares, the days-to-cover ratio is currently 4.6 days. Currently, 5.8% of the company's shares are sold short.
View OraSure Technologies' Short Interest

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for OraSure Technologies

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings results on Tuesday, August, 3rd. The medical instruments supplier reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.06. The medical instruments supplier had revenue of $57.61 million for the quarter, compared to analysts' expectations of $56.50 million. OraSure Technologies had a trailing twelve-month return on equity of 1.33% and a net margin of 2.34%.
View OraSure Technologies' earnings history

How has OraSure Technologies' stock been impacted by Coronavirus (COVID-19)?

OraSure Technologies' stock was trading at $5.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OSUR shares have increased by 126.8% and is now trading at $13.38.
View which stocks have been most impacted by COVID-19

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies updated its third quarter 2021 earnings guidance on Tuesday, August, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45 million-$50 million, compared to the consensus revenue estimate of $67.88 million.

What price target have analysts set for OSUR?

3 brokers have issued twelve-month price targets for OraSure Technologies' stock. Their forecasts range from $12.50 to $15.00. On average, they anticipate OraSure Technologies' share price to reach $14.17 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for OraSure Technologies
or view top-rated stocks among Wall Street analysts.

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the following people:
  • Stephen S. Tang, President, Chief Executive Officer & Director
  • James Ted Rauth, Senior Vice President-Operations
  • Roberto E. Cuca, Chief Financial Officer
  • Jack E. Jerrett, Secretary, Chief Compliance Officer & Senior VP
  • Kathleen G. Weber, EVP-Business Unit Leader & Molecular Solutions

What is Stephen Tang's approval rating as OraSure Technologies' CEO?

2 employees have rated OraSure Technologies CEO Stephen Tang on Stephen Tang has an approval rating of 100% among OraSure Technologies' employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of OraSure Technologies' key competitors?

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (19.53%), Bank of America Corp DE (7.33%), Bank of America Corp DE (7.33%), Vanguard Group Inc. (6.61%), American Capital Management Inc. (5.08%) and State Street Corp (4.55%).
View institutional ownership trends for OraSure Technologies

Which institutional investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Prudential Financial Inc., Vanguard Group Inc., Victory Capital Management Inc., Wells Fargo & Company MN, Balyasny Asset Management LLC, Goldman Sachs Group Inc., and AQR Capital Management LLC.
View insider buying and selling activity for OraSure Technologies
or view top insider-selling stocks.

Which institutional investors are buying OraSure Technologies stock?

OSUR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Systematic Financial Management LP, Morgan Stanley, Morgan Stanley, Bank of America Corp DE, Bank of America Corp DE, State Street Corp, and AXA S.A..
View insider buying and selling activity for OraSure Technologies
or or view top insider-buying stocks.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $13.38.

How much money does OraSure Technologies make?

OraSure Technologies has a market capitalization of $963.48 million and generates $171.72 million in revenue each year. The medical instruments supplier earns $-14,920,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does OraSure Technologies have?

OraSure Technologies employs 570 workers across the globe.

What is OraSure Technologies' official website?

The official website for OraSure Technologies is

Where are OraSure Technologies' headquarters?

OraSure Technologies is headquartered at 220 EAST FIRST STREET, BETHLEHEM PA, 18015.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at (610) 882-1820 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.